Hypothyroidism
Classic Symptoms
- Fatigue, cold intolerance, weight gain, constipation
- Bradycardia, dry skin, hair loss, periorbital oedema
- Myxoedema in severe untreated cases
- Depression, impaired cognition, menorrhagia
Levothyroxine Nursing Points
- Early morning fasting — 30–60 min before food/other meds
- Drug interactions: calcium, iron, PPIs reduce absorption — separate by 4h
- Start dose 1.6 mcg/kg/day; elderly start 25 mcg and titrate slowly
- Annual TFT monitoring once stable; 6-weekly if adjusting dose
- Pregnancy: TSH target <2.5 mIU/L — increase dose 25-30% immediately
Hyperthyroidism
Causes in GCC
- Graves' disease (autoimmune — TSH-receptor antibodies)
- Toxic nodular goitre (common with iodine fluctuation)
- Thyroiditis (postpartum thyroiditis prevalent in GCC women)
- Excess iodine/amiodarone-induced
Antithyroid Therapy
- Carbimazole: 20–40 mg/day titration; CBC for agranulocytosis
- PTU preferred in first trimester and thyroid storm
- Block-replace protocol: high-dose carbimazole + replacement T4 for 18 months
- Instruct: report sore throat/fever immediately — agranulocytosis risk
Radioiodine (I-131) Nursing Care
Radiation Precautions
- Avoid close contact (<1 metre) with children and pregnant women for 7–14 days
- Sleep in separate bed for 6 nights; flush toilet twice
- Increase fluid intake; avoid public transport for 3–5 days
- Thyroid swelling and pain normal at 7–10 days post-dose
- Monitor TFTs at 4–6 weeks; hypothyroidism expected
ABSOLUTE CONTRAINDICATIONPregnancy and breastfeeding — exclude with beta-hCG before administration. Contraception mandatory 6–12 months post-treatment.
Exacerbation RiskRisk of Graves' ophthalmopathy flare. Pre-treat with prednisolone if moderate-severe eye disease. Document baseline eye exam.
THYROID STORM — Medical Emergency
HIGH MORTALITY 10–30% — Activate Rapid Response ImmediatelyBurch-Wartofsky Point Scale (BWPS): Score ≥45 = thyroid storm; 25–44 = impending storm
Burch-Wartofsky Scoring
| Parameter | Points |
|---|
| Temp 37.2–37.7°C | 5 |
| Temp 38.3–38.8°C | 15 |
| Temp >40°C | 30 |
| HR 100–109 | 5 |
| HR >140 | 25 |
| Heart failure (mild) | 5 |
| Agitation/delirium | 10 |
| Seizure/coma | 30 |
| Precipitant identified | 10 |
Treatment Protocol (in order)
- PTU 500–1000 mg loading then 250 mg Q4H — blocks synthesis AND conversion
- Lugol's iodine 5–10 drops Q6H — given 1 hour AFTER PTU
- Propranolol 60–80 mg Q4H PO or IV for HR control
- Hydrocortisone 100 mg IV Q8H — blocks T4→T3 conversion
- Active cooling — paracetamol (NOT aspirin — displaces T4 binding)
- IV fluid resuscitation, glucose monitoring, electrolytes
- Identify and treat precipitant (infection, surgery, RAI, non-compliance)
Post-Thyroidectomy Complications Monitoring
Hypocalcaemia (Hours 1–24)
Peak risk 24–72 hours post-opCheck calcium Q4H for first 24h. Parathyroid glands may be temporarily/permanently damaged.
- Chvostek's sign: Tap facial nerve → ipsilateral facial twitch
- Trousseau's sign: BP cuff inflated 20 mmHg above systolic for 3 min → carpal spasm
- Symptoms: perioral tingling, muscle cramps, anxiety, seizures
- Mild: oral calcium carbonate 1-2g + calcitriol 0.25 mcg BD
- Severe/symptomatic: calcium gluconate 10 mL 10% IV slow over 10 min
Recurrent Laryngeal Nerve (RLN) Injury
- Unilateral: hoarseness, weak voice — usually temporary 6–12 weeks
- Bilateral: stridor, respiratory distress — EMERGENCY re-intubation
- Assess voice quality on return from theatre and Q4H
- Keep emergency airway equipment at bedside
- Speech therapy referral if hoarseness persists >2 weeks
Other Post-op Watch
- Haematoma: neck swelling, stridor — return to theatre
- Wound: check dressing, drain output hourly for 4h
- Hypothyroidism: start levothyroxine at discharge
Adrenal Insufficiency Comparison
| Feature | Primary (Addison's) | Secondary |
|---|
| Cortisol | ↓ Low | ↓ Low |
| ACTH | ↑ High | ↓ Low |
| Aldosterone | ↓ Low | Normal |
| Sodium | ↓ Hyponatraemia | ↓ Mild |
| Potassium | ↑ Hyperkalaemia | Normal |
| Skin | Hyperpigmentation | Pale/normal |
| BP | Postural hypotension | Low-normal |
| Cause | Autoimmune, TB, adrenalectomy | Pituitary/steroid withdrawal |
Sick Day Rules — Patient Education
Instruct All Adrenal Insufficiency PatientsCortisol demand increases 2–3x during illness/surgery. Failure to increase dose can precipitate adrenal crisis.
Dose Adjustment Guidelines
- Fever >38°C / moderate illness: DOUBLE oral dose
- Severe illness / vomiting / unable to absorb: TRIPLE or switch to IM hydrocortisone
- Surgery (minor): 25 mg hydrocortisone IV at induction
- Surgery (major): 100 mg IV at induction then 50 mg Q6H × 24h, then taper
- Unable to take oral for any reason: hydrocortisone IM/IV immediately
- Always carry Emergency Steroid Card and wear medical alert bracelet
- Carry emergency hydrocortisone 100 mg IM kit with instructions
ADRENAL CRISIS — EMERGENCY
Life-threatening — Treat immediately, INVESTIGATE LATERSuspect in: known adrenal insufficiency + acute illness/surgery, or unexplained shock/hypoglycaemia/confusion
Immediate Actions
- Hydrocortisone 100 mg IV/IM STAT — do not delay for investigations
- 0.9% NaCl 1L IV over 30–60 min; continue aggressive resuscitation
- Check glucose STAT — 10% dextrose if <4 mmol/L
- Hydrocortisone 200 mg/24h via continuous IV infusion OR 50 mg Q6H
- Identify and treat precipitating cause
- Monitor: HR, BP, BGL Q1H, UO, electrolytes Q4–6H
Clinical Presentation
- Severe hypotension / shock unresponsive to fluids
- Profound weakness, nausea, vomiting, abdominal pain
- Hypoglycaemia (especially children)
- Hyponatraemia, hyperkalaemia, hypercalcaemia
- Confusion, reduced consciousness
- Fever (may mimic sepsis)
Steroid CardProvide written steroid card documenting: drug, dose, diagnosis, sick day rules, emergency instructions, prescriber contact.
Cushing's Syndrome
Diagnostic Tests — Nursing Role
- Midnight cortisol: sample at 23:00–00:00; patient must be asleep or at complete rest; falsely elevated if stressed/acutely ill
- Low-dose dexamethasone suppression test: give 1 mg dexamethasone at 23:00; cortisol measured at 08:00 next morning — failure to suppress (>50 nmol/L) = positive
- 24h urinary free cortisol: patient education on complete collection; avoid strenuous exercise
Clinical Features & Nursing Concerns
- Hypertension: strict BP monitoring, antihypertensives
- Hyperglycaemia: glucose monitoring, diabetes management
- Skin fragility: use paper tape, avoid trauma, pressure area care
- Proximal myopathy: fall risk assessment, mobility aids
- Immunosuppression: infection surveillance, isolation precautions
- Osteoporosis: DEXA scan, fall prevention, bisphosphonates
- Psychiatric: depression, psychosis screening — safety assessment
Phaeochromocytoma
Avoid Beta-blockers First — Can Cause Hypertensive CrisisAlpha-blockade must be established BEFORE any beta-blocker is introduced. Unopposed alpha stimulation = severe vasoconstriction.
Clinical Features
- Paroxysmal hypertension (episodic BP spikes >200 systolic)
- Triad: headache, palpitations, diaphoresis (sweating)
- Pallor (not flushing), anxiety, tremor
- Hyperglycaemia during episodes
Preoperative Alpha-blockade
- Phenoxybenzamine 10 mg BD, titrated over 10–14 days pre-op
- Monitor for postural hypotension — encourage fluid intake/salt loading
- Beta-blocker ONLY after adequate alpha-blockade (usually 5–7 days after)
- Avoid: dopamine antagonists, opioid pethidine, glucagon, histamine
- Intraoperative BP swings: ensure nitroprusside/phentolamine available
Panhypopituitarism — Replacement Sequence (CRITICAL ORDER)
Sequence is Critical — Thyroid before Cortisol can precipitate Adrenal CrisisCortisol deficiency masks hypothyroidism. Replace cortisol FIRST to avoid crisis when thyroid hormone is introduced.
1st
Hydrocortisone (cortisol)
2nd
Levothyroxine (thyroid)
3rd
Growth Hormone (if indicated)
4th
Sex Steroids (testosterone/oestrogen)
5th
Desmopressin (if DI present)
Nursing Monitoring Points
- Ensure sick day rules apply for hydrocortisone — patient education essential
- TSH unreliable in central hypothyroidism — use free T4 for monitoring
- GH therapy: administer SC at night, monitor for fluid retention, glucose
- Sex steroid replacement: bone density monitoring, cardiovascular risk assessment
Acromegaly — GH Excess
Clinical Features
- Acral enlargement: jaw (prognathism), hands, feet — ring/shoe size increase
- Frontal bossing, wide spacing of teeth, skin thickening
- Carpal tunnel syndrome (bilateral), arthropathy
- Hypertension, cardiomegaly, sleep apnoea (CPAP often required)
- Glucose intolerance / diabetes (GH antagonises insulin)
- Headache, bitemporal hemianopia (if macroadenoma)
Management
- Surgery: transsphenoidal adenomectomy — first-line
- Octreotide LAR 20–30 mg IM monthly — nursing: rotate gluteal injection sites, GI side effects, gallstones surveillance
- Cabergoline: oral, cheaper, less effective for GH
- Monitoring: IGF-1 level (not GH — due to pulsatility), visual fields, echocardiogram
Prolactinoma — Most Common Pituitary Tumour
Clinical Features by Sex
- Women: galactorrhoea (milk discharge), amenorrhoea, infertility, osteoporosis
- Men: erectile dysfunction, reduced libido (often late diagnosis), visual symptoms
- Macroprolactinoma (>10mm): visual field defect (bitemporal hemianopia) — urgent
Cabergoline Therapy
- Cabergoline 0.5 mg twice weekly, titrated to prolactin level
- More effective than bromocriptine with better tolerability
- Nausea and postural hypotension (take with food, evening dose)
- Cardiac valve monitoring for doses >2 mg/week (echocardiogram annually)
Visual Field Monitoring — MacroprolactinomaFormal perimetry (Goldmann/Humphrey) before treatment and at 3-month intervals. Deteriorating vision = urgent imaging + consider surgery.
Central Diabetes Insipidus (CDI)
Diagnostic Criteria
- Polyuria: urine output >3 L/day (may exceed 10–20 L/day)
- Urine osmolality <300 mOsm/kg (dilute urine)
- Plasma osmolality >295 mOsm/kg (concentrated blood)
- Urine: plasma osmolality ratio <1 (diagnostic of DI)
- Water deprivation test: failure to concentrate urine → confirms DI
- Desmopressin (DDAVP) response distinguishes central from nephrogenic
Desmopressin (DDAVP) Nursing
- Intranasal 10–20 mcg BD; oral 0.1–0.2 mg BD/TDS; SC/IM options
- Monitor: strict fluid balance, daily weight, serum sodium
- Risk of hyponatraemia (water intoxication) — do not encourage excess fluid
- Post-neurosurgery: DI often transient (24–48h); monitor carefully
SIADH — Syndrome of Inappropriate ADH
Diagnostic Features
| Finding | SIADH |
|---|
| Serum sodium | <135 (hyponatraemia) |
| Serum osmolality | <275 (dilute blood) |
| Urine osmolality | >100 (concentrated) |
| Urine sodium | >20 mEq/L |
| Volume status | Euvolaemic |
| Thyroid/adrenal | Must be normal |
Management
- Mild (Na 130–134): fluid restriction 800–1000 mL/24h
- Moderate (Na 125–129): fluid restrict + salt tablets if tolerated
- Severe (Na <120 or symptomatic): hypertonic saline 3% — specialist only
- Correction rate: max 8–10 mmol/L in 24h — too fast → osmotic demyelination syndrome (ODS)
- Vaptans (tolvaptan) for chronic SIADH — monitor liver function
- Identify and treat underlying cause: malignancy, CNS, pulmonary, drugs
Hyperparathyroidism
| Parameter | Primary HPT | Secondary HPT | Tertiary HPT |
|---|
| Calcium | ↑ High | Normal/↓ | ↑ High |
| Phosphate | ↓ Low | ↑ High | ↑ High |
| PTH | ↑ High | ↑ High | ↑↑ Very high |
| Cause | Adenoma (85%) | CKD/Vit D def. | CKD — autonomous |
Symptoms — "Bones, Stones, Groans, Moans"
- Bones: osteoporosis, osteitis fibrosa cystica, bone pain
- Stones: renal calculi (calcium oxalate/phosphate)
- Groans: nausea, vomiting, constipation, pancreatitis
- Moans: depression, anxiety, cognitive impairment
Management Options
- Surgery: parathyroidectomy — definitive for symptomatic/Ca²⁺ >2.85 mmol/L
- Cinacalcet 30–90 mg/day: calcimimetic — lowers PTH/calcium; monitor nausea
- Bisphosphonates: for bone protection if surgery declined
- Adequate hydration 2–3 L/day to prevent renal stones
Hypercalcaemia of Malignancy
Calcium >3.5 mmol/L = Hypercalcaemic CrisisMost common metabolic emergency in cancer. PTHrP (PTH-related protein) mediates 80% of cases.
Emergency Management
- IV 0.9% NaCl rehydration: 200–300 mL/hr initially — restores GFR
- Loop diuretics (frusemide) ONLY after rehydration if fluid overload
- Zoledronic acid 4 mg IV over 15 min (renal adjusted) — effect in 24–48h
- Denosumab 120 mg SC — alternative if renal impairment
- Calcitonin 4–8 IU/kg SC/IM Q6–12H — rapid onset (6h), tachyphylaxis in 48h
- Steroids (prednisolone 40 mg/day) effective for haematological malignancy
- Dialysis if life-threatening refractory hypercalcaemia
Hypocalcaemia — Post-Surgical Emergency & Signs
Neuromuscular Signs
Chvostek's SignTap facial nerve 2 cm anterior to tragus of ear. Positive = ipsilateral facial muscle twitch. Sensitivity ~25%; can be positive in normals.
Trousseau's Sign (More Specific)Inflate BP cuff to 20 mmHg above systolic for 3 minutes. Positive = carpal spasm (wrist flexion, thumb adduction, finger extension). Sensitivity 94% for hypocalcaemia.
- Perioral/finger tingling, laryngospasm, bronchospasm
- Prolonged QT on ECG — risk of cardiac arrhythmia
- Tetany, seizures in severe cases
Treatment Protocol
| Severity | Treatment |
|---|
| Symptomatic/acute | Calcium gluconate 10 mL of 10% IV over 10–20 min; repeat if needed |
| Infusion | Calcium gluconate 40 mL in 500 mL NaCl/D5W over 4–6h |
| Mild/chronic | Oral calcium carbonate 1–2 g/day + calcitriol 0.25–0.5 mcg BD |
| Monitoring | Corrected serum Ca²⁺ Q4H post-thyroid/parathyroid surgery |
Corrected Calcium FormulaCorrected Ca = Measured Ca + 0.02 × (40 − Albumin g/L). Always correct for albumin level.
Vitamin D Deficiency — GCC Context
Paradox: Highest UV-B Exposure, Highest Vitamin D DeficiencyPrevalence 30–90% across GCC populations. Drivers: sun avoidance (heat), modest dress, indoor lifestyle, darker skin phototype, exclusive breastfeeding without supplementation.
Supplementation Protocols
| Level (nmol/L) | Classification | Treatment |
|---|
| <25 | Severe deficiency | Cholecalciferol 50,000 IU weekly × 8 weeks then monthly |
| 25–49 | Deficiency | Cholecalciferol 50,000 IU weekly × 4–6 weeks then maintenance |
| 50–74 | Insufficiency | Cholecalciferol 2,000 IU daily or 50,000 IU monthly |
| 75–250 | Sufficient | Maintenance 1,000–2,000 IU daily |
| >375 | Toxicity risk | Withhold — hypercalcaemia risk |
- UAE/Saudi MOH: mandatory D3 fortification of dairy products and infant formula
- Newborns: 400 IU/day from day 1 (breastfed) per GCC paediatric guidelines
- Pregnant/lactating: 1,500–2,000 IU/day minimum; check baseline 25-OH-D
- Link to autoimmune thyroid disease, insulin resistance, depression, MS in GCC
Osteoporosis — DEXA & Treatment
T-Score Classification
| T-Score | Diagnosis | Action |
|---|
| ≥−1.0 | Normal | Lifestyle advice, Ca/D supplementation |
| −1.0 to −2.5 | Osteopenia | Calcium + D3, fracture risk assessment |
| ≤−2.5 | Osteoporosis | Bisphosphonate + Ca + D3 therapy |
| ≤−2.5 + fracture | Severe OP | Specialist review, anabolic therapy |
Bisphosphonate Administration — Monthly Tablet Technique
- Alendronate 70 mg or risedronate 35 mg once weekly on same day
- Take on empty stomach with full glass of water (200–250 mL)
- Remain upright (sitting/standing) for 30 min after — prevents oesophagitis
- No food, drink or other medications for 30 min post-dose
- Dental review before IV bisphosphonates — osteonecrosis of jaw risk
- Monitoring: serum calcium/phosphate/creatinine before IV doses
- Renal threshold: withhold if eGFR <35 mL/min (IV) or <30 (oral)
Diabetic Ketoacidosis (DKA)
Diagnostic Criteria (All 3 Must Be Present)
BGL >11
mmol/L (or known DM)
Ketones ↑
blood ≥3 or urine 2+
DKA Severity Classification
| Severity | pH | Bicarb | Mental Status |
|---|
| Mild | 7.25–7.30 | 15–18 | Alert |
| Moderate | 7.10–7.25 | 10–15 | Alert/drowsy |
| Severe | <7.10 | <10 | Stuporous/coma |
Treatment Protocol
- Fluid: 0.9% NaCl 1L over 30–60 min (if haemodynamically unstable: faster); then 1L/2h × 2, then 1L/4h × 2, then 1L/6h
- Insulin: 0.1 unit/kg/hr fixed-rate IV insulin (FRIII); do NOT bolus unless senior instruction
- Potassium: Add 40 mmol KCl/L if K⁺ 3.5–5.5; HOLD insulin if K⁺ <3.5 until replaced
- Switch to 5% dextrose when BGL <14 mmol/L (maintain insulin infusion)
- Continue insulin until blood ketones <0.6 mmol/L AND pH >7.3
- BGL target: 10–14 mmol/L during resolution — too rapid drop risks cerebral oedema
- Identify and treat precipitant: infection (most common), insulin omission, new diagnosis
Cerebral Oedema — Paediatric DKA WarningMost common cause of death in children with DKA. Risk factors: age <5 years, new diagnosis, excessive fluid/rapid correction. Fluid rate CAUTION: max 10 mL/kg/hr. Signs: headache, deteriorating consciousness, bradycardia/hypertension, fixed dilated pupils. TREAT: mannitol 0.5–1 g/kg IV STAT, call neurosurgery.
Hyperosmolar Hyperglycaemic State (HHS)
Distinguishing Features from DKA
| Feature | DKA | HHS |
|---|
| Onset | Hours–days | Days–weeks |
| Ketosis | Significant | Absent/minimal |
| pH | <7.3 | Normal (>7.3) |
| Glucose | Often 15–30 | Usually >30–60 |
| Osmolality | Mildly elevated | Markedly >320 |
| Dehydration | Moderate | Severe (8–10 L deficit) |
| Patient type | Type 1 (mainly) | Type 2 elderly |
Management — Cautious Fluid Protocol
- 0.9% NaCl: cautious rate — maximum 500 mL/hr initially; adjust to serum osmolality
- Target osmolality reduction: max 3–8 mOsm/kg/hr — too fast → cerebral oedema
- Insulin: WITHHOLD until BGL falls to <20 mmol/L on fluids alone — fluids are primary treatment
- Insulin rate: 0.05 unit/kg/hr (half of DKA rate) when started
- LMWH/heparin for VTE prophylaxis — high thrombotic risk from hyperviscosity
- Monitor electrolytes (especially sodium) Q2H, urine output hourly
- Effective Na = Measured Na + 2.4 × [(Glucose − 5.6) / 5.6]
Hypoglycaemia — DEFG Rule
D·E·F·G — Don't Ever Forget GlucoseBGL <4.0 mmol/L = hypoglycaemia in diabetic patient. BGL <2.8 mmol/L = severe hypoglycaemia.
Severity & Treatment
| Level | BGL | Treatment |
|---|
| Mild | 3.0–3.9 | 15g fast carbs: 3 glucose tablets or 150 mL juice/cola; recheck 15 min |
| Moderate | 2.0–2.9 | Hypostop buccal gel (GlucoGel) or oral glucose if conscious |
| Severe | <2.0 or unconscious | IV glucose 150–200 mL of 10% over 15 min; OR glucagon IM/IN |
Glucagon Administration
- Glucagon 1 mg IM (thigh/deltoid) if IV access unavailable and unconscious
- Intranasal glucagon (Baqsimi) 3 mg — easier for community/relatives
- Onset IM glucagon: 10–15 min; place patient in recovery position
- After recovery: give long-acting carbohydrate (sandwich, biscuits)
- Glucagon ineffective in alcohol-related hypoglycaemia or hepatic failure
Post-Episode Monitoring Protocol
- Recheck BGL at 15 min after treatment — if still <4, repeat glucose
- After stabilisation: BGL Q30 min × 2h, then Q1H × 4h
- Document: time, BGL, symptoms, treatment given, response
- Identify cause: missed meal, excess insulin, alcohol, exercise
- Review insulin regimen: may need dose reduction
- Severe/recurrent: endocrinology review before discharge
Hypostop / GlucoGel — Nursing Points
- Place inside cheek if gag reflex present — do NOT use in fully unconscious patient
- Massage outside of cheek to aid absorption
- Each tube = 10g dextrose; may use 2 tubes if needed
- Check airway throughout procedure — aspiration risk
GCC Diabetes Epidemic — Global Leader
16–20%
Adult DM prevalence UAE/Saudi/Qatar
#1
GCC leads globally by prevalence
50%
Undiagnosed cases estimated
80%
Type 2 proportion in GCC
Contributing Factors
- Rapid lifestyle transition: sedentary urbanisation, car culture
- High refined carbohydrate diet: white rice, dates, processed foods
- Obesity rates: 35–40% of GCC adults (BMI >30) — among world's highest
- Vitamin D deficiency → insulin resistance → beta-cell dysfunction cycle
- Genetic predisposition: Gulf Arab metabolic phenotype
- Consanguinity: higher risk of MODY and rare DM forms
- Physical inactivity: heat-driven indoor lifestyle year-round
- Gestational DM: high prevalence → offspring at risk of T2DM
Ramadan & Diabetes — Endocrine Society Guidelines
Endocrine Society / IDF-DAR Ramadan GuidelinesIndividualised risk stratification mandatory before Ramadan. Fasting >15 hours significantly alters drug pharmacodynamics and metabolic risk.
Risk Classification for Fasting
| Risk | Profile | Advice |
|---|
| Very high | Type 1 DM, severe hypoglycaemia history, poor control HbA1c >10% | Strongly advised NOT to fast |
| High | Unstable T2DM, pregnant DM, CKD stage 3+, dialysis | Medical clearance required |
| Moderate/Low | Well-controlled T2DM on oral agents or basal insulin | Fasting possible with education |
Type 1 DM — ExemptionType 1 patients are medically exempt from fasting in Islam (religious ruling). Nurses should convey this sensitively and support informed decision-making.
Medication Adjustments
- Metformin: shift main dose to Iftar; continue if tolerated
- Sulphonylureas (SU): HIGH hypoglycaemia risk — consider stopping or halving dose at Suhoor
- SGLT2 inhibitors (dapagliflozin/empagliflozin): UTI risk from dehydration; DKA risk (euglycaemic DKA) — consider discontinuation during Ramadan
- GLP-1 agonists: continue; may help with post-Iftar hyperglycaemia
- Basal insulin: reduce dose 20–30% at Suhoor; shift injection to before Iftar
- Rapid insulin: omit Suhoor dose; administer at Iftar and Tarawih meal
Monitoring During Ramadan
- BGL monitoring is permitted and should be encouraged (does not break fast — scholarly consensus)
- Break fast if BGL <4 mmol/L or >16.7 mmol/L (symptomatic)
- Iftar glucose surge: avoid immediate large carbohydrate load — start with dates + water, then protein
- Post-Ramadan: review all doses — hyperglycaemia risk as eating pattern resumes
Thyroid Disorders in GCC Women
- Hashimoto's thyroiditis and Graves' disease both more prevalent in GCC women
- Vitamin D deficiency → impaired immune regulation → autoimmune thyroid disease
- Veiling (covering) + avoidance of sun = severe D deficiency → thyroid autoimmunity
- Hypothyroidism screening recommended in all GCC women planning pregnancy
- Postpartum thyroiditis: 5–10% of women; often missed as postnatal depression
- Iodised salt mandatory in all GCC countries since late 1990s (WHO mandate)
- Goitre from iodine fluctuation: monitor carefully in coastal vs inland populations
Consanguinity & Rare Endocrine Genetics
GCC Consanguinity Rate 25–60%First-cousin marriage (legal and culturally accepted). Higher incidence of autosomal recessive endocrine conditions vs global average.
Conditions to Screen for in GCC
- MEN1 (Multiple Endocrine Neoplasia Type 1): parathyroid + pituitary + pancreatic tumours. MENIN gene. Consider in young hyperparathyroidism, insulinoma, prolactinoma clusters in families
- MEN2A: medullary thyroid cancer + phaeochromocytoma + hyperparathyroidism. RET proto-oncogene. Annual calcitonin + metanephrine screening in affected families
- Congenital adrenal hyperplasia (CAH): CYP21A2 mutations — 21-hydroxylase deficiency. Ambiguous genitalia, precocious puberty, salt-wasting crisis in neonates
- MODY (Maturity-Onset Diabetes of the Young): consider in young DM without autoimmunity, family history, no obesity — genetic testing panel
- Familial hypocalciuric hypercalcaemia (FHH): CASR mutation — mimics primary hyperparathyroidism; parathyroidectomy inappropriate
GCC National Health Programmes — Nurse Awareness
UAE (MOH)
- National Diabetes Programme (NDP): universal annual fasting glucose screening adults >30
- Mandatory vitamin D fortification: milk, infant formula, bread
- Weqaya programme: cardiovascular & diabetes prevention
- DM telemedicine expansion post-COVID
Saudi Arabia (MOH)
- Vision 2030 diabetes management integration into primary care
- Mandatory iodised salt since 1993
- Vitamin D supplementation policy: mandatory in children, pregnant women
- Saudi Endocrine Society guidelines for Ramadan management widely adopted
Qatar / Kuwait / Oman / Bahrain
- Qatar: national DM registry at Hamad Medical Corporation
- Kuwait: free insulin/supplies for all registered DM patients
- Oman: notable success in early detection programmes; community nurses role central
- Bahrain: MOH annual thyroid/DM screening campaigns
Obesity-Insulin Resistance-T2DM Cycle in GCC
Nurse's Role in Breaking the CycleIdentify high-risk patients early: central obesity (waist >90 cm men / >80 cm women in GCC populations), acanthosis nigricans, polycystic ovary syndrome (PCOS), first-degree relative with T2DM. Refer to multidisciplinary team: dietitian (culturally adapted — halal, traditional foods), exercise physiologist, endocrinologist, diabetes educator.